Drugs / Ra-223 Dichloride
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01833520 | Oct 2013 → Apr 2020 | sarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02366130 | Feb 2015 → Dec 2020 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ra-223 dichloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02366130 ↗ |
| Modality | Other / unclassified | “Radium-223 chloride is designed to work like radiation therapy in cells that are actively making bone.” NCT01833520 ↗ |
| Route | Intravenous | “50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.” NCT01833520 ↗ |